Immunoglobulin Nephropathy
📧 Sign up to get email alerts when something new happens for Immunoglobulin Nephropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-04Clinical Trial Update: Atrasentan in Patients With IgA Nephropathy [Phase 3]
Phase 3 trial update for atrasentan in IgA nephropathy is active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) [Phase 3]
Phase 3 trial of sibeprenlimab in immunoglobulin A nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Results: Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy [Phase 2]
Phase 2 trial assessing efficacy and safety of Felzartamab (MOR202), a human anti-CD38 antibody, in IgA nephropathy; study completed with re…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Chinese Adults With Kidney Disease [Phase 2]
ADARx Pharmaceuticals is conducting a Phase 2 trial in Chinese adults with immunoglobulin A nephropathy, C3 glomerulopathy, or immune comple…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) [Phase 3]
This is a Phase 3 clinical trial to study felzartamab infusions in adults with Immunoglobulin A Nephropathy (IgAN), currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) [Phase 3]
Phase 3 clinical trial evaluating Ravulizumab for Immunoglobulin A Nephropathy is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. [Phase 1, Phase 2]
An early-phase (Phase 1/2) study of MIL116 is currently recruiting healthy participants and patients with Immunoglobulin A nephropathy to ev…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Assess the Effects of Zigakibart on IgA Nephropathy. [Phase 2]
A Phase 2 clinical trial to assess the effects of Zigakibart on Immunoglobulin A Nephropathy is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN [Phase 2]
A Phase 2 clinical trial evaluating iptacopan added to standard of care in adults with immunoglobulin A nephropathy to assess biopsy changes…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis [Phase 4]
This clinical trial update indicates that sparsentan is being studied in Phase 4 for posttransplant immunoglobulin A nephropathy and focal s…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) [Phase 3]
A Phase 3 clinical trial evaluating sibeprenlimab for Immunoglobulin A nephropathy is ongoing, with the study currently active but not recru…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. [Phase 3]
Open-label extension study of Zigakibart in adults with Immunoglobulin A nephropathy is in Phase 3 and currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) [Phase 2]
A Phase 2 study of ravulizumab in proliferative lupus nephritis and immunoglobulin A nephropathy has been terminated, with results posted in…
-
CLINICAL_TRIALS trial_result · 2025-12-17Clinical Trial Update: Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) [Phase 3]
Phase 3 clinical trial evaluating the efficacy of povetacicept in adults with Immunoglobulin A nephropathy; the study is currently active bu…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN [Phase 2]
A Phase 2 study evaluating the safety and effectiveness of sparsentan in combination with an SGLT2 inhibitor in immunoglobulin A nephropathy…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy [EARLY_Phase 1]
A clinical trial entry indicates that Cizutamig is being studied in immunoglobulin A nephropathy and is currently in EARLY Phase 1 with enro…
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
A Novartis-sponsored mobile app-based study in the United States aims to evaluate disease burden and treatment patterns in Immunoglobulin A …
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. [Phase 4]
Clinical trial update for a multicenter Phase 4 study evaluating personalized therapy in patients with Immunoglobulin A Nephropathy, current…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: First in Human Study to Assess Safety of VIS649 in Healthy Subjects [Phase 1]
First-in-human Phase 1 study to assess the safety of VIS649 in healthy subjects has completed and results have been posted.
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy [Phase 2, Phase 3]
An open-label Phase 2/3 study of Sibeprenlimab for Immunoglobulin A nephropathy is currently enrolling by invitation.
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Safety and Efficacy Study of VIS649 for IgA Nephropathy [Phase 2]
Phase 2 safety and efficacy study of VIS649 for Immunoglobulin A nephropathy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301 [Phase 3]
Phase 3 trial Nef-301 evaluating efficacy and safety in Chinese patients with Immunoglobulin A nephropathy has completed.
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) [Phase 2]
Phase 2 study evaluating safety and tolerability of BCX9930 in complement-mediated kidney diseases was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade [Phase 2]
Open-label Phase 2 study to evaluate safety and efficacy of CCX168 in subjects with immunoglobulin A nephropathy on stable RAAS blockade; st…
-
CLINICAL_TRIALS trial_result · 2017-11-30Clinical Trial Update: Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 [Phase 3]
This clinical trial update reports the start of Phase 3 evaluation for a treatment targeting Immunoglobulin A nephropathy (IgA nephropathy) …